Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panel
Jenny F. Seligmann(University of Leeds), Michel Seymour(University of Leeds), Sabine Tejpar(KU Leuven), Faye Elliott(University of Leeds), Philip Quirke(University of Leeds), Bart Jacobs, Jennifer H. Barrett(University of Leeds), Sarah Brown(University of Leeds), Gemma Hemmings(University of Leeds), Christopher J.M. Williams(Hospital for Special Surgery), Susan D. Richman(University of Leeds)
Cited by 18
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial
|The Lancet|2009|1.5k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k